Relation of serum homocysteine and lipoprotein(a) concentrations to atherosclerotic disease in a prospective Finnish population based study

Atherosclerosis

Volumn 106, Issue 1, 1994, Pages 9-19

  Alfthan, G ^a   Pekkanen, J ^a   Jauhiainen, M ^a   Pitkaniemi J ^a   Karvonen, M ^a   Tuomilehto, J ^a   Salonen, J T ^b   Ehnholm, C ^a  

^a NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^b UNIVERSITY OF EASTERN FINLAND   (Finland)

Author keywords

Atherosclerotic disease; Homocysteine; Lipoprotein(a); Myocardial infarction; Prospective study; Stroke

Indexed keywords

HOMOCYSTEINE; LIPOPROTEIN A;

ADULT; ARTICLE; ATHEROSCLEROSIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FINLAND; GENE FREQUENCY; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; REGRESSION ANALYSIS; STROKE;

ADULT; ARTERIOSCLEROSIS; CASE-CONTROL STUDIES; CEREBROVASCULAR DISORDERS; FEMALE; FINLAND; FOLLOW-UP STUDIES; HOMOCYSTEINE; HUMANS; LIPOPROTEIN(A); MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYOCARDIAL INFARCTION; ODDS RATIO; PROSPECTIVE STUDIES; REGRESSION ANALYSIS; RISK FACTORS;

EID: 0028219672     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/0021-9150(94)90078-7     Document Type: Article

References (54)

1. Disorders of transsulfuration
2. Homocystinuria associated with decreased methylenetetrahydrofolate reductase activity
3. Isolation and characterization of methionine synthetase from human placenta
4. Plasma homocysteine, a risk factor for vascular disease. Plasma levels in health, disease, and drug therapy
5. The natural history of homocystinuria due to cystathionine 0-synthase deficiency
6. Oxidation of low-density lipoprotein bythiol compounds leads to its recognition by the acetyl LDL receptor
7. The role of sulfur-containing amino acids in superoxide production and modification of low density lipoprotein by arterial smooth muscle cells.
8. Homocystinemia. Vascular injury and arterial thrombosis
9. Protein-bound homocyst(e)ine. A possible risk factor for coronary artery disease
10. Prevalence of hyperhomocyst(e)inemia in patients with peripheral arterial occlusive disease
11. Homocyst(e)inemia in daily practice: levels in coronary artery disease
12. The association of elevated homocyst(e)ine with progression of symptomatic peripheral arterial disease
13. Plasma homocyst(e)ine levels in men with premature coronary artery disease
14. The prevalence of homocystinemia and hypercholesterolemia in angio graphically defined coronary heart disease
15. Elevated plasma homocyst(e)ine concentration as a possible independent risk factor for stroke
16. Plasma sulhydryl-containing amino acids in patients with cerebral infarction and in hypertensive subjects
17. Hyperhomocyst(e)inemia in Utah siblings with early coronary disease
18. A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in US physicians
19. Folic acid — an innocuous means to reduce plasma homocysteine
20. Impaired homocysteine metabolism in early-onset cerebral and peripheral occlusive arterial disease. Effects of pyridoxine and folic acid treatment
21. Vitamin B-l2, vitamin B-6, and folate nutritional status in men with hyperhomocysteinemia
22. Methionine intolerance: a possible risk factor for coronary artery disease
23. Heterozygosity for homocystinuria in premature periphral and cerebral occlusive arterial disease
24. Homocysteine and myocardial infarction
25. Hyperhomocysteinemia: an independent risk factor for vascular disease
26. Studies on the Lp(a)-lipoprotein of human serum. IV The disaggregation of the Lp(a)-lipoprotein
27. Characterization of the Lp(a) lipoprotein in human plasma
28. Protein composition of Lp(a) lipoprotein from human plasma
29. Purification and quantitation of the human plasma lipoprotein carrying the Lp(a) antigen
30. Protein and carbohydrate composition of Lp(a) lipoprotein from human plasma
31. The occurrence of Ag determinants in different lipoproteins
32. The mysteries of lipoprotein(a)
33. cDNA sequence of human apolipoprotein(a) is homologous to plasminogen
34. Serum lipids in angiographically assessed coronary atherosclerosis
35. Lipoprotein Lp(a) and the risk for myocardial infarction
36. Lp(a) lipoprotein as a risk factor for coronary heart disease and cerebral infarction
37. The association between serum Lp(a) concentrations and angiographically assessed coronary atherosclerosis. De pendence on serum LDL levels
38. Lp(a) lipoprotein as a risk factor for myocardial infarction
39. Association of levels of lipoprotein Lp(a), plasma lipids and other lipoproteins with coronary artery disease documented by angiography
40. Lipoprotein Lp(a), a risk factor for myocardial infarction
41. Lipoprotein(a) is an independent risk factor for myocardial infarction at a young age
42. Lipoprotein(a) and coronary heart disease risk: a nested casecontrol study of the Helsinki Heart Study participants
43. Lipoproteins and their genetic variation in subjects with and without angiographically verified coronary artery disease
44. Determination of free and total homocysteine in human plasma by high-performance liquid chromatography with fluorescence detection
45. Diseases of Finland and Scandinavia
46. Detection of heterozygotes for recessive alleles. Homocyst(e)inemia: paradigm of pitfalls in phenotypes
47. Elevation of total homocysteine in the serum of patients with cobalamin or folate deficiency detected by capillary gas chromatography-mass spectrometry
48. Lipoprotein(a) in relation to atherosclerotic diseases
49. Lipoprotein(a) and coronary heart disease: a prospective case control study in a general pop ulation sample of middle aged men
50. Evidence for increased levels of plasminogen activator inhibitor and tissue plasminogen activator in plasma of patients with angiographically verified coronary artery disease